Empowering Recovery

It's time to break the COPD exacerbation cycle.

AerobiKA

77% of COPD patients have experienced an exacerbation, increasing risk of hospitalization and driving disease progression.[1]

COPD=Chronic Obstructive Pulmonary Disease


029 10:55:17
DAYS HOURS MINS SECS
April
SUN MON TUE WED THU FRI SAT
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30

The countdown to her next COPD exacerbation has already begun.

It is estimated that **6.5 million** people globally have moderate to severe COPD.[2]

These patients are prone to exacerbations[3], having 1 to 2 exacerbations per year.[4]

Acute exacerbations are the **most common reason** for medical visits, hospital admissions, and death in patients with COPD.[5]

1 in 5 patients hospitalized for a COPD exacerbation require re-hospitalization **within 30 days**.[6]

Post-exacerbation airways in crisis: **30 days** – the critical post-exacerbation period.

During an exacerbation, airways are compromised by inflammation, mucus buildup, and dynamic lung hyperinflation[7]



After an exacerbation, these factors disrupt the mechanics of ventilation and normal lung function, leading to prolonged respiratory impairment[7]

Delaying recovery beyond 30 days
places patients at risk for further airway deterioration and recurrent exacerbations[6]

Post-exacerbation recovery.

According to the GOLD Guidelines, the goal for treatment of COPD exacerbations is to **minimize the negative impact** of the current exacerbation and to **prevent subsequent events**.[8]

Reduces COPD exacerbations by 28% in the critical 30 day period[9]



Results from the same real-world study indicated:

- Lower oral corticosteroid and antibiotic use at 30 days following an exacerbation event ($p \leq 0.0001$ for both)
- A trend towards decreased length of hospital stay (2.2 days) $p > 0.05$

Improves lung function in COPD[10]



FVC=Forced Vital Capacity

Improves ventilation in COPD[10]

Before
Baseline care

After
Baseline care plus ***Aerobika**** device



Hyperpolarized ^{3}He magnetic resonance imaging (MRI)

Teal colour and intensity show areas with gas distribution. Yellow circles represent areas of greatest change **after 3-4 weeks of *Aerobika**** device use.

An effective addition to COPD disease management

NNT=17

The ***Aerobika**** device can help prevent 1 hospitalization within 30 days for every 17 patients treated derived from 9

NNT=Number Needed to Treat

Evidence supports the *Aerobika** device as an add-on to usual care to manage COPD patients post-exacerbation

Improves quality of life in COPD[11]

Responder rates for improvements greater than the Minimum Clinically Important Difference[11]



SGRQ=St. George's Respiratory Questionnaire; CAT=COPD Assessment Test
† Randomized, cross-over study evaluating the efficacy of the ***Aerobika**** device after 3-4 weeks of treatment in patients with COPD and chronic bronchitis.
‡ Clinical assessment of patients with COPD and chronic bronchitis over 8 weeks of treatment with the ***Aerobika**** device.

The *Aerobika** device. Therapeutic Guide

Post-exacerbation therapy

For the critical 30 days after an exacerbation –

Administer for 10 minutes, twice daily.

Long-term control

For ongoing airway maintenance –

Continue to administer at least once a day.

HOW THE *AEROBIKA** DEVICE WORKS

Designed to address the structural and functional challenges in post-exacerbation airways



The ***Aerobika**** device is drug-free and easy to use

- ***Oscillations*** are maintained from the start to the end of each breath
- ***Resistance settings*** adjust to each patient's capacity
- ***Operation independent*** from orientation
- ***Easy to clean*** and ***disinfect***

EASY TO USE

AerobiKA® PATIENT OUTCOMES

In a patient satisfaction survey, 97% of respondents said they would continue to use the *Aerobika*® device.[15†]

- ***Drug-free***, handheld device designed to address the structural and functional challenges in the airways of patients with COPD
- ***Clinically proven*** to reduce exacerbations and increase lung function[9,10]
- ***Improves*** patient quality of life[11]

†Patient satisfaction survey given to 812 patients after ≥3 weeks of twice-daily use of the ***Aerobika***® device.

Prescribe the *Aerobika*® device for post-exacerbation recovery.

References: 1. Barnes N, *et al.* BMC Pulm Med 2013;13(54):1-11. 2. World Health Organization. Available from: www.who.int/respiratory/copd/burden/en/ (Last accessed 16 July 2018). 3. Seemungal TA, *et al.* Am J Respir Crit Care Med 1998;157:1418-1422. 4. MacNee W, *et al.* Thorax 2003;58:261-265. 5. Lawati NAI, *et al.* BCMJ 2008;50(3):138-142. 6. Shah T, *et al.* CHEST 2016;150(4):916-926. 7. O'Donnell DE, Parker CM. Thorax 2006;61:354-361. 8. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available from: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf (Last accessed June 2018). 9. Burudpakdee C, *et al.* Pulm Ther 2017;3(1):163-171. 10. Svenningsen S, *et al.* J COPD 2016;13(1):66-74. 11. Stockley RA. Abstract presentations: COPD10, Birmingham, United Kingdom, 2016. Chronic Obstr Pulm Dis. 2017; 4(3): 225-246. 12. Wolkove N, *et al.* CHEST 2002;121(3):702-707. 13. Suggett J, *et al.* Abstract presented at: COPD11. June 20-21, 2018. Birmingham, United Kingdom. 14. Mussche C, *et al.* Poster presented at: American Thoracic Society Annual Conference. May 18-23, 2018. San Diego, United States. 15. Harkness H, *et al.* Poster presented at: Canadian Respiratory Conference. April 23-25, 2015. Ottawa, Canada.

Trudell Medical International®

Manufactured by: Trudell Medical International
725 Third Street, London, Ontario, Canada, N5V 5G4
+1-519-455-7060 customerservice@trudellmed.com

Designed and Developed in Canada

aerobika.ca

MEDICAL DESIGN EXCELLENCE AWARDS® 2014 GOLD WINNER